Subsequent Events	3 Months Ended
Mar. 31, 2023
Disclosure Text Block
Subsequent Events	16. Subsequent Events Effective April 30, 2023, the Company entered into a Mutual Termination Agreement with Roche, pursuant to which the parties mutually agreed to terminate the Roche immunotherapy agreement. Pursuant to the Termination Agreement, the rights and licenses granted by the Company to Roche related to MAP4K1 have terminated in their entirety. Certain licenses granted by Roche to the Company survived and became exclusive, worldwide, perpetual, royalty-free and irrevocable. Further, the Company retained ownership of the collaboration compounds directed to MAP4K1 and all other previously terminated kinase targets developed under the collaboration.

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI https://asc.fasb.org/topic&trid=2122774

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662

Name:	us-gaap_SubsequentEventsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration